Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2013

01-01-2013 | Letter

Pioglitazone and risk of bladder cancer: clarification of the design of the French study

Author: A. T. Perez

Published in: Diabetologia | Issue 1/2013

Login to get access

Excerpt

To the Editor: In the July 2012 issue of this journal, Neumann et al [1] presented results from a cohort study using data from the French national health insurance information system. In this paper, the authors report that pioglitazone exposure in patients aged 40–79 years was significantly associated with an increased risk of bladder cancer (adjusted HR 1.22 [95% CI 1.05, 1.43]). …
Literature
1.
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55:1953–1962PubMedCrossRef
2.
Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with Pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922PubMedCrossRef
3.
4.
Metadata
Title
Pioglitazone and risk of bladder cancer: clarification of the design of the French study
Author
A. T. Perez
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2767-y

Other articles of this Issue 1/2013

Diabetologia 1/2013 Go to the issue

Article

Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation

Review

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Article

Long-term exposure to traffic-related air pollution and diabetes-associated mortality: a cohort study

Review

Type 2 diabetes and cardiovascular disease in women

Research Letter

Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype

Article

Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits